Cardiology

The US Food and Drug Administration has approved bumetanide nasal spray for the treatment of edema in outpatient heart, liver, and kidney diseases.

Research shows reduced risk of death, major adverse cardiovascular events, and myocardial infarction, and a non-significant reduction in stroke and cardiovascular death.

Compared to standard devices, the first-of-its-kind AIRE-CHB model indicated incident CHB risk, outperforming standard ECG devices.

Life’s Essential 8 scores are substantially lower among adults aged ≥65 years who exhibit high blood pressure, stroke, or other cardiovascular diseases.

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 5 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 4 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 3 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 2 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 1 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

Wang and colleagues analyzed data from nearly 105,000 patients to create and test a device that can predict the efficacy of various drug combinations for hypertension.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 clinical trial data, in this week's essential news roundup.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

The death rate from high blood pressure-related kidney disease increased by 48% from 1999-2023, with notable disparities by race, ethnicity, sex, and region.

Patel addresses the updated AHA/ACC hypertension guidelines, explaining important features and highlighting the potential of newer therapies.

Bhalla breaks down the newer treatments included in the recently updated AHA/ACC hypertension management guidelines.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Despite an excellent safety and tolerability profile and proven efficacy in treating atrial fibrillation, PFA failed to prove superiority to RA.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.